Law Debenture Corporation plc (LON:LWDB) has announced its fact sheet as at 30th October 2026:
Fund Managers’ Comments
In October the Trust’s NAV fell 0.6%, underperforming the FTSE All-Share benchmark which rose 1.1%. In a backdrop where the oil price rose and the sustainability of AI capital expenditure was being questioned, there was a sharp rotation in markets with defensive sectors outperforming. Oil producers such as Shell and BP performed well (both share prices rose 13-14% in October), as did data services companies Relx and LSEG (where the share prices rose 20% and 16% respectively). While Relx and LSEG had been seen as at risk of AI disintermediation earlier in the year, a further set of encouraging quarterly results led to a sharp relief rally. In contrast, cyclical sectors such as industrials performed poorly, as investors questioned whether rising input costs and a potential slowdown in AI capex would suppress future earnings growth. Industrial holdings such as Hill & Smith therefore performed poorly. Aside from industrials, the key detractors
from the portfolio compared to its FTSE All-Share benchmark were holding less in large index weights that performed well, such as Shell and AstraZeneca, and holding more in AI-exposed next generation energy companies, for example fuel cell developer Ceres Power. We had taken substantial profits in Ceres earlier this calendar year, and the position size is now modest at less than 1%.
From a transactions perspective, within the healthcare sector we sold the positions in Swiss pharmaceutical Roche and US medical devices company Becton Dickinson following good performance. The proceeds were partially rotated into AstraZeneca and GSK. In the case of AstraZeneca, following the initial purchase last month we have continued to gradually add to the holding, while in the case of GSK we added on what we saw as an overreaction to a largely in line set of
quarterly results.
James Henderson and Laura Foll
Janus Henderson







































